Abstract |
Although the immune status of chronic lymphocytic leukemia (CLL) patients is mostly characterized by immunosuppression, there is an accumulation of in vivo (graft-versus- leukemia effect) and in vitro (spontaneous remissions after infections) data that indicates that CLL might be effectively targeted by T-cell based immunotherapy. Recently, we characterized receptor for hyaluronic acid mediated motility (RHAMM) as a preferential target for immunotherapy of CLL. We also completed a RHAMM-derived peptide vaccination phase I/II clinical trial in CLL. Here, we present a detailed immunological analysis of six CLL patients vaccinated with HLA-A2 restricted RHAMM-derived epitope R3 (ILSLELMKL). Beside effective induction of R3-specific cytotoxic T-cells, peptide vaccination caused profound changes in different T-cell subsets as well as cytokines. We present longitudinal analyses of Th17, CD8(+)CD103(+), CD8(+)CD137(+) and IL-17 producing CD8(+) T cells (CD8(+)IL- -17(+)) as well as important cytokines involved in regulation of immune response such as TGF-β, IL-10, IL-2 and TNF throughout the peptide vaccination period.
|
Authors | Krzysztof Giannopoulos, Paulina Własiuk, Anna Dmoszyńska, Jacek Roliński, Michael Schmitt |
Journal | Folia histochemica et cytobiologica
(Folia Histochem Cytobiol)
Vol. 49
Issue 1
Pg. 161-7
( 2011)
ISSN: 1897-5631 [Electronic] Poland |
PMID | 21526504
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Cancer Vaccines
- Cytokines
- Peptide Fragments
|
Topics |
- Adult
- Aged
- Cancer Vaccines
(adverse effects, immunology)
- Cytokines
(blood, immunology)
- Enzyme-Linked Immunosorbent Assay
- Female
- Humans
- Leukemia, Lymphocytic, Chronic, B-Cell
(diagnosis, immunology, therapy)
- Male
- Middle Aged
- Peptide Fragments
(adverse effects, immunology)
- T-Lymphocyte Subsets
(drug effects, immunology, pathology)
- Vaccination
|